Recent advances in understanding APDS pathogenesis have led to the development of targeted therapies, including mTOR inhibitors (e.g., sirolimus) and PI3Kδ-specific inhibitors, offering new hope for effective and personalized treatment. The gene discussed is MTOR; the disease is activated PI3K-delta syndrome.